Logo
x

Search

Subscribe Now

CASI

CASI Entered into a Sublicense Agreement with Tianshi for CID-103 to Treat Autoimmune Diseases

CASI Entered into a Sublicense Agreement with Tianshi for CID-103 to Treat Autoimmune Diseases

  • May 25, 2022
PharmaShots Weekly Snapshots (Dec 28- 31, 2020)

PharmaShots Weekly Snapshots (Dec 28- 31, 2020)

  • December 31, 2020
Regeneron Reports IDMC Clearance of Efficacy for REGEN-COV (Casirivimab + Imdevimab) in P-III COVID-19 Outpatient Outcomes Trial

    Regeneron Reports IDMC Clearance of Efficacy for REGEN-COV (Casirivimab + Imdevimab) in P-III COVID-19 Outpatient Outcomes Trial

    • February 26, 2021
    PharmaShots Weekly Snapshots (Dec 28- 31, 2020)

      PharmaShots Weekly Snapshots (Dec 28- 31, 2020)

      • December 31, 2020
      CASI Pharmaceutical Signs an Exclusive Worldwide License Agreement with Black Belt for its TSK011010 Program

        CASI Pharmaceutical Signs an Exclusive Worldwide License Agreement with Black Belt for its TSK011010 Program

        • April 18, 2019
        Image

        Incisive News in 3 Shots.

        Contact Us

        Our Information

        Follow Us

        Copyright © 2025 PharmaShots - All Rights Reserved.